Curis (CRIS) Stock Price, News & Analysis

Company Overview

Curis, Inc. is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors. The company’s earlier success includes the development of vismodegib, marketed as Erivedge® through a collaboration and subsequent acquisition by Genentech, for the treatment of advanced basal cell carcinoma. Curis continues to pursue partnerships to advance its pipeline and leverage external expertise for product registration and commercialization.

Founded in 1997 and headquartered in Lexington, Massachusetts, Curis operates research facilities in the greater Boston area and collaborates with academic institutions and industry partners worldwide. The company’s integrated discovery and development platform has been instrumental in generating therapeutic candidates across multiple cancer indications, with a strategic focus on precision medicines that offer the potential for improved patient outcomes and differentiated safety profiles.

Curis is led by President and Chief Executive Officer Ali Fattaey, Ph.D., who joined the company in 2019 and brings extensive experience in oncology research and drug development. The senior management team comprises seasoned professionals in clinical development, regulatory affairs and commercial strategy, underscoring Curis’ commitment to advancing its pipeline candidates through critical regulatory milestones and toward potential market approval.

Key Stats

• Today's Range: $4.92 to $5.17
• 50-Day Range: $4.12 to $11.34
• 52-Week Range: $3.61 to $39.00
• Volume: 14,190 shs
• Average Volume: 84,062 shs
• Market Capitalization: $9.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.00
• Consensus Rating: Hold

Curis Stock Analysis - MarketRank™

Curis scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Curis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Curis has a consensus price target of $43.00, representing about 756.6% upside from its current price of $5.02.

Amount of Analyst Coverage

Curis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Curis are expected to grow in the coming year, from ($33.29) to ($18.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Curis is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Curis is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Curis has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.74% of the float of Curis has been sold short.

Short Interest Ratio / Days to Cover

Curis has a short interest ratio ("days to cover") of 0.95, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Curis has recently decreased by 97.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Curis does not currently pay a dividend.

Dividend Growth

Curis does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.25

News Sentiment

Curis has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Curis this week, compared to 3 articles on an average week.

Search Interest

Only 6 people have searched for CRIS on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Curis insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.78% of the stock of Curis is held by insiders.

Percentage Held by Institutions

29.97% of the stock of Curis is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 8/02/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CRIS
• CIK: 1108205
• Web: www.curis.com
• Phone: (617) 503-6500
• Fax: 617-503-6501
• Employees: 60
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Curis: $43.00
• High Price Target: $43.00
• Low Price Target: $43.00
• Potential Upside/Downside: +756.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($23.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.58 million
• Net Margins: -80.29%
• Pretax Margin: -299.66%
• Return on Equity: N/A
• Return on Assets: -181.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.11
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: $9.44 million
• Price / Sales: 1.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.45 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 1,950,000
• Free Float: 1,836,000
• Market Cap: $9.79 million
• Optionable: No Data
• Beta: 3.13